JAGX
Jaguar Health, Inc.Company Information
- Company Name
- Jaguar Health, Inc.
- CIK
- CIK0001585608
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- JAGX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- JAGX
SEC filing data through
Insider Sentiment
- Last purchase
- 2022-12-31
- Last sale
- 2021-06-04
- Shares purchased (TTM)
- 317
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 5,311
- Shares outstanding
- 809,122
- Ownership
- 0.66%
Earnings Market Reaction
- Filing date
- 2026-08-19
- Price on filing date
- —
- 1-month reaction
- -66.02%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Series G Convertible Preferred Stock | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 4 | 7 | 1 | 4 | 2 | 6 | 8 | 13 | 16 | 12 | 6 | 3 | ||||||
| Restricted Cash Current | 3 | 3 | 7 | - | - | - | 0 | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 0 | 0 | 2 | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 2 | ||||||
| Other Receivables Net Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Inventory Net | 7 | 8 | 9 | 11 | 11 | 11 | 10 | 10 | 10 | 9 | 9 | 8 | ||||||
| Prepaid Expense And Other Assets Current | 3 | 2 | 2 | 14 | 14 | 13 | 12 | 12 | 13 | 11 | 10 | 9 | ||||||
| Assets Current | 18 | 20 | 20 | 29 | 28 | 30 | 32 | 37 | 40 | 34 | 28 | 22 | ||||||
| Property Plant And Equipment Net | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Operating Lease Right Of Use Asset | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Intangible Assets Net Excluding Goodwill | 15 | 16 | 16 | 17 | 18 | 18 | 18 | 19 | 19 | 20 | 20 | 21 | ||||||
| Other Assets | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 1 | ||||||
| Assets | 34 | 37 | 38 | 49 | 48 | 51 | 53 | 58 | 61 | 55 | 51 | 45 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 5 | 5 | 9 | 8 | 7 | 7 | 5 | 5 | 4 | 3 | 5 | 5 | ||||||
| Accrued Liabilities Current | 5 | 4 | 4 | 4 | 4 | 2 | 2 | 3 | 3 | 3 | 4 | 3 | ||||||
| Contract With Customer Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | - | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | ||||||
| Notes Payable Current | 14 | 22 | 27 | 23 | 19 | 19 | 12 | 11 | 11 | 10 | 5 | 4 | ||||||
| Liabilities Current | 25 | 41 | 41 | 36 | 29 | 28 | 20 | 20 | 19 | 18 | 14 | 12 | ||||||
| Operating Lease Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | ||||||
| Contract With Customer Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | - | - | ||||||
| Derivative Liabilities Noncurrent | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Long Term Notes Payable | 2 | 11 | 15 | 8 | 11 | 18 | 24 | 22 | 22 | 22 | 31 | 31 | ||||||
| Liabilities | 29 | 53 | 57 | 45 | 41 | 48 | 44 | 43 | 42 | 41 | 46 | 44 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | 0 | 0 | 2 | 2 | 2 | 2 | 2 | - | - | ||||||
Stockholders Equity | ||||||||||||||||||
| Additional Paid In Capital Common Stock | 412 | 378 | 381 | 381 | 374 | 359 | 354 | 351 | 344 | 330 | 314 | 301 | ||||||
| Minority Interest | -2 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -0 | -0 | 0 | ||||||
| Retained Earnings Accumulated Deficit | -404 | -391 | -400 | -377 | -367 | -357 | -346 | -337 | -327 | -317 | -308 | -299 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -1 | -1 | -1 | -1 | -1 | -1 | -0 | -1 | -1 | -0 | -1 | -1 | ||||||
| Stockholders Equity | 5 | -16 | -19 | 4 | 7 | 1 | 6 | 13 | 17 | 12 | 5 | 1 | ||||||
| Liabilities And Stockholders Equity | 34 | 37 | 38 | 49 | 48 | 51 | 53 | 58 | 61 | 55 | 51 | 45 | ||||||
| Common Stock | -0 | 0 | 0 | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | ||||||
| Series H Convertible Preferred Stock | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | -2 | ||||||
| Convertible Non Voting Common Stock | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Notes Payable Fair Value Disclosure | - | - | - | - | - | - | - | - | - | - | 31 | 30 | ||||||
| Temporary Equity Par Or Stated Value Per Share | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | ||||||
| Temporary Equity Shares Authorized | - | - | - | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | ||||||
| Series J Redeemable Preferred Stock | - | - | 0 | - | - | - | 0 | - | - | - | - | - | ||||||
| Convertible Preferred Stock Series B Two | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Series C Perpetual Preferred Stock | - | - | - | - | - | - | 1 | - | - | - | 1 | - | ||||||
| Series I Convertible Preferred Stock | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Series B Convertible Preferred Stock | - | - | - | - | - | - | 0 | - | - | - | 0 | - | ||||||
| Series K Junior Participating Preferred Stock | - | - | - | - | - | 0 | - | - | - | - | - | - | ||||||
| Series L Perpetual Preferred Stock | 0 | 0 | 0 | -0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Series M Perpetual Preferred Stock | 0 | 0 | 0 | 0 | 0 | - | 0 | - | - | - | - | - | ||||||
| Series N Perpetual Preferred Stock | 0 | 0 | 0 | 0 | - | - | 0 | - | - | - | - | - | ||||||
| Series P Perpetual Preferred Stock | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Series Q Perpetual Preferred Stock | 0 | - | - | - | - | - | - | - | - | - | - | - | ||||||
| Series O Convertible Preferred Stock | 0 | 0 | - | - | - | - | - | - | - | - | - | - | ||||||
| Common Stock Voting | -298 | 298 | 0 | 4 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Nonvoting Common Stock | -0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Issued | - | - | - | - | - | - | - | - | - | - | - | 26 | ||||||
| Preferred Stock Shares Authorized | 4 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | - | ||||||
| Temporary Equity Shares Issued | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Temporary Equity Shares Outstanding | - | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialJaguar Health, Inc. (JAGX) — SEC Financial Statements & Analysis
Jaguar Health, Inc. (JAGX) is a pharmaceutical preparations company, incorporated in DE. Jaguar Health, Inc. trades on Nasdaq as: JAGX. Jaguar Health, Inc. (JAGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-19. Based on that filing, Jaguar Health, Inc. carries a market cap of $36.41M, a P/E ratio of -0.70x, a P/B ratio of 7.40x, a P/S ratio of 1.31x, an enterprise value of $45.38M, and an EV/EBITDA multiple of -1.89x. On profitability, it posts a gross margin of 82.31%, an operating margin of -93.10%, a net margin of -188.35%, a Return on Equity (ROE) of -887.87%, a Return on Assets (ROA) of -127.06%, and a Return on Invested Capital (ROIC) of -106.41%. Per share, it reports EPS of $-64.75, diluted EPS of $-64.75, free cash flow per share of $-8.26, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 135.52% year-over-year, net income growth of 28.48% year-over-year, and EPS growth of -95.40% year-over-year. On the balance sheet, it maintains a current ratio of 0.69x, a quick ratio of 0.27x, working capital of $-7.85M, a debt-to-equity ratio of 5.95x, a debt ratio of 0.86, an interest coverage ratio of -25.95x, free cash flow of $-6.68M (TTM), and net debt of $8.97M. Figures sourced from SEC EDGAR.
- Market Cap
- $36.41M
- P/E TTM
- -0.70x
- EPS TTM
- $-64.75
- P/B TTM
- 7.40x
- ROE TTM
- -887.87%
- ROA TTM
- -127.06%
- Debt To Equity
- 5.95x
- Free Cash Flow TTM
- $-6.68M
- Net Revenue TTM Growth 1Y
- 135.52%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Jaguar Health, Inc. in?
Jaguar Health, Inc. (JAGX) operates in the Pharmaceutical Preparations industry.
What exchange does JAGX trade on?
Jaguar Health, Inc. (JAGX) trades on the Nasdaq.
Where is Jaguar Health, Inc. incorporated?
Jaguar Health, Inc. is incorporated in DE.
When was Jaguar Health, Inc. (JAGX)'s most recent SEC filing?
Jaguar Health, Inc. (JAGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-19.
What is JAGX's market cap?
Jaguar Health, Inc. (JAGX) has a market capitalization of $36.41M as of 2026-06-30.
What is JAGX's EPS (earnings per share)?
Jaguar Health, Inc. (JAGX)'s trailing twelve month EPS is $-64.75 as of 2026-06-30.
What is JAGX's ROE (return on equity)?
Jaguar Health, Inc. (JAGX)'s trailing twelve month Return on Equity (ROE) is -887.87% as of 2026-06-30.
What is JAGX's ROA (return on assets)?
Jaguar Health, Inc. (JAGX)'s trailing twelve month Return on Assets (ROA) is -127.06% as of 2026-06-30.
What is JAGX's ROIC (return on invested capital)?
Jaguar Health, Inc. (JAGX)'s trailing twelve month Return on Invested Capital (ROIC) is -106.41% as of 2026-06-30.
What is JAGX's EV/EBITDA?
Jaguar Health, Inc. (JAGX)'s trailing twelve month EV/EBITDA is -1.89x as of 2026-06-30.